In vivo最新文献

{"title":"<i>In Vivo</i> Antitumor Activity of Allicin in a Pediatric Neuroblastoma Patient-derived Xenograft (PDX) Mouse Model.","authors":"Chad R Schultz, Martin C H Gruhlke, Alan J Slusarenko, André S Bachmann","doi":"10.21873/invivo.13932","DOIUrl":"https://doi.org/10.21873/invivo.13932","url":null,"abstract":"<p><strong>Background/aim: </strong>Allicin is a small-molecule natural product found in garlic (Allium sativum). We previously showed that allicin inhibits ornithine decarboxylase (ODC) <i>in vitro</i> and induces apoptotic cell death in pediatric neuroblastoma (NB) cancer cell cultures. However, its potency as an anticancer agent <i>in vivo</i> has not been sufficiently explored.</p><p><strong>Materials and methods: </strong>In this study, we used cell proliferation assays, immunoblotting techniques, and light microscopy to study NB tumor cell cultures and human primary neonatal skin fibroblast control cells as well as a <i>MYCN</i>-amplified NB patient-derived xenograft (PDX) mouse tumor model to study the efficacy of allicin <i>in vivo</i>.</p><p><strong>Results: </strong>Allicin strongly inhibits NB tumor cell proliferation in a dose-dependent manner while non-cancerous human primary neonatal skin fibroblast control cells were largely unaffected. Importantly, two intra-tumoral injections of allicin over a two-week trial period significantly reduced the NB tumor burden in mice compared to controls (N=4-9 mice/group). Excised tumor tissues revealed that allicin treatment increased the cyclin-dependent kinase inhibitor p27^Kip1 protein levels, suggesting that <i>in vivo</i>, allicin increases p27^Kip1-mediated G₁/S cell cycle arrest.</p><p><strong>Conclusion: </strong>Our findings warrant further preclinical development of allicin as a potential anticancer agent, especially for those types of cancers that are treatable by intra-tumoral injections, including neuroblastoma, glioblastoma, and medulloblastoma.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1283-1292"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Frailty and Drug Burden Index in Older Hospitalized Patients.","authors":"Yukako Morisaki, Misuzu Takashima, Ayako Maeda-Minami, Sayaka Izumi, Masanori Suzuki, Ryohkan Funakoshi, Yasunari Mano","doi":"10.21873/invivo.13971","DOIUrl":"https://doi.org/10.21873/invivo.13971","url":null,"abstract":"<p><strong>Background/aim: </strong>In a super-aging society, understanding the prescription status of drug burden index (DBI) drugs that have anticholinergic and sedative effects in patients with frailty to consider proper medical intervention and promote appropriate drug use for older adults is important. This study evaluated the association between frailty and the use of DBI drugs in older hospitalized patients using hospital electronic medical records.</p><p><strong>Patients and methods: </strong>This cross-sectional study included patients admitted to the Kameda Medical Center between October 1, 2016 and October 31, 2017. Patients with a Barthel Index of <90 or Mini-Mental State Examination score of <18 or otherwise were classified into the frailty and non-frailty groups, respectively. DBI drugs fall into nine categories based on previous studies, and 162 drugs marketed in Japan were included. Patients using DBI drugs were considered DBI drug users; otherwise, patients were considered DBI drug non-users. Comparisons of the DBI drug proportions in both groups were performed using logistic regression analysis while adjusting for patient background factors and calculating the adjusted odds ratios and 95% confidence intervals.</p><p><strong>Results: </strong>The proportion of DBI drug users was significantly lower in the frailty group compared to the non-frailty group (adjusted odds ratio=0.32, 95% confidence interval=0.24-0.42, <i>p</i><0.001).</p><p><strong>Conclusion: </strong>Hospitalized older patients with frailty in Japan may be associated with a lower risk of DBI drug use and may use drugs with caution. In clinical practice, drug treatment for older patients may be implemented in consideration of various patient backgrounds, including frailty.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1694-1792"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Reactions With VEGF Inhibitors in Combination With NSAIDs: Disproportionality Analysis Using JADRE and FAERS.","authors":"Kazuki Saito, Satoru Nihei, Junichi Asaka, Kenzo Kudo","doi":"10.21873/invivo.13947","DOIUrl":"https://doi.org/10.21873/invivo.13947","url":null,"abstract":"<p><strong>Background/aim: </strong>The concurrent use of vascular endothelial growth factor (VEGF) inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs) raises concerns regarding the increased risk of adverse drug reactions (ADRs) due to potential pharmacodynamic interactions. However, no studies have specifically addressed this issue. The objective of this study was to investigate whether the combination of these drugs increased the risk of ADRs.</p><p><strong>Patients and methods: </strong>Disproportionality analysis was conducted on ADR reports from the Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS) databases. The concomitant signal score and Ω shrinkage measure were used to identify safety signals associated with the drug combination. Additionally, logistic regression analysis focused on reports of ADRs related to cancer treatment and assessed the significance of the adjusted reporting odds ratio (aROR) for the interaction between these drugs.</p><p><strong>Results: </strong>Disproportionality analysis included ADR data from the JADER (<i>n</i>=1,509,399) and FAERS (<i>n</i>=38,610,433) databases. The concomitant signal score and Ω shrinkage measure identified a signal for gastrointestinal perforation in both databases. Logistic regression on cancer treatment-related ADRs (JADER: <i>n</i>=255,177; FAERS: <i>n</i>=1,167,941) showed a synergistic increase in gastrointestinal perforation risk with the drug combination [aROR for interaction term: JADER: 1.74 (95% confidence interval (CI)=1.45-2.07); FAERS: 1.49 (95% CI=1.29-1.72)].</p><p><strong>Conclusion: </strong>The combination of VEGF inhibitors and NSAIDs is associated with an increased risk of gastrointestinal perforation, a serious and potentially fatal ADR. Therefore, caution is warranted when prescribing a combination of these drugs.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1458-1469"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Venous Access for Cardiac Resynchronization Therapy in a Hemodialysis Patient With Cabozantinib-associated Heart Failure.","authors":"Amane Otoi, Akinori Higaki, Noriyoshi Miura, Keisho Kurokawa, Kohei Yoshimoto, Tomoaki Nishikawa, Rikako Horie, Arisa Abe, Yasuhisa Nakao, Tomoki Fujisawa, Shigehiro Miyazaki, Yusuke Akazawa, Toru Miyoshi, Hiroshi Kawakami, Haruhiko Higashi, Shunsuke Tamaki, Kazuhisa Nishimura, Katsuji Inoue, Shuntaro Ikeda, Osamu Yamaguchi","doi":"10.21873/invivo.13973","DOIUrl":"https://doi.org/10.21873/invivo.13973","url":null,"abstract":"<p><strong>Background: </strong>Cabozantinib, a multi-targeted tyrosine kinase inhibitor, is widely used for the treatment of renal and hepatic cancers. While cabozantinib-associated cardiotoxicity is rare, it has been documented in several cases. In most instances, cancer therapeutics-related cardiac dysfunction (CTRCD) is managed by discontinuing cabozantinib and initiating cardioprotective agents. In this report, we present the case of a 63-year-old male with cabozantinib-induced heart failure (HF) with reduced ejection fraction (EF) and complete left bundle branch block (CLBBB).</p><p><strong>Case report: </strong>The patient, undergoing hemodialysis for chronic kidney disease, had limited therapeutic options due to prior treatment failures. Despite six months of standard HF therapy, symptoms persisted, prompting cardiac resynchronization therapy (CRT) implantation without interrupting cabozantinib. Due to the presence of a dialysis shunt in the patient's left arm, the right subclavian vein was selected for venous access to minimize the risk of lead-related complications. Using a tunneling tool, the left ventricular lead was placed <i>via</i> the contralateral vasculature to the ipsilateral generator. Six months post-CRT, echocardiography showed significant reverse remodeling with improved EF and reduced left ventricular end-diastolic diameter, alongside clinical symptom relief.</p><p><strong>Conclusion: </strong>This case highlights the utility of bilateral venous access with a tunneling tool in cardiac resynchronization therapy, particularly for patients with hemodialysis shunts.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1719-1723"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil-to-Lymphocyte Ratio as a Biomarker for Postoperative Complications in Crohn's Disease.","authors":"Makoto Kawamoto, Daijiro Higashi, Ken Kinjo, Noritaka Takatsu, Yoshihiro Miyasaka, Hisatomi Arima, Satoshi Nimura, Takashi Hisabe, Masato Watanabe","doi":"10.21873/invivo.13958","DOIUrl":"https://doi.org/10.21873/invivo.13958","url":null,"abstract":"<p><strong>Background/aim: </strong>Despite advances in diagnosis and pharmacotherapy, surgery remains crucial for Crohn's disease (CD). Postoperative intra-abdominal septic complications (IASC) occur in 1.2-16.7% of cases. We investigated the frequency of postoperative IASC in elective surgeries for CD and the risk factors and potential biomarkers for postoperative IASC.</p><p><strong>Patients and methods: </strong>We conducted a retrospective single-center cohort study of patients who underwent abdominal surgery for CD at Fukuoka University Chikushi Hospital between January 2015 and December 2023. The primary focus was the incidence of IASC within 60 days postoperatively. Patient-related variables were examined using univariate and multivariable analyses.</p><p><strong>Results: </strong>The analysis included 206 of 249 surgeries. Postoperative IASC occurred in 26 patients (12.6%). Univariate analysis identified history of steroid use requiring steroid coverage (<i>p</i>=0.002), penetrating type (<i>p</i>=0.020), WBC count (<i>p</i>=0.037), neutrophil count (0.009), C-reactive protein (CRP) (<i>p</i>=0.035), CRP-albumin ratio (CAR) (<i>p</i>=0.034), neutrophil-to-lymphocyte ratio (NLR) (<i>p</i>=0.002), and operation duration (<i>p</i>=0.010) as significant factors. Multivariable analysis identified history of steroid use requiring steroid coverage (OR=6.23, 95%CI=1.61-24.1, <i>p</i>=0.008), high NLR (OR=3.43, 95%CI=1.30-9.04, <i>p</i>=0.013), and long duration of operation (OR=2.63, 95%CI=1.01-6.88, <i>p</i>=0.049) as independent predictors. The optimal cutoffs for predicting IASC were an NLR of 3.98 (sensitivity, 61.5%; specificity, 77.8%) and an operation time of 173 min (sensitivity, 65.4%; specificity, 65.0%), respectively.</p><p><strong>Conclusion: </strong>History of steroid use requiring steroid coverage, preoperative NLR ≧3.98, and duration of operation ≧173 min are independent risk factors for postoperative IASC in elective surgeries for CD. Recognition of high-risk patients would contribute to the decision-making process for perioperative management.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1580-1590"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Feasibility of Common Enterotomy Closure Using Bidirectional Barbed Sutures in Intracorporeal Overlap Anastomosis During Robotic Surgery for Colon Cancer.","authors":"Masatsune Shibutani, Tatsunari Fukuoka, Hiroaki Kasashima, Shintaro Ozawa, Hideki Tanda, Ken Yonemitsu, Yuki Seki, Kiyoshi Maeda","doi":"10.21873/invivo.13956","DOIUrl":"https://doi.org/10.21873/invivo.13956","url":null,"abstract":"<p><strong>Background/aim: </strong>Although intracorporeal anastomosis in minimally invasive colectomy has many advantages, it requires a longer operative time than extracorporeal anastomosis. For quick and reliable common enterotomy closure, we proposed a new method using bidirectional barbed sutures. The present study evaluated the safety and feasibility of common enterotomy closure using bidirectional barbed sutures in intracorporeal overlap anastomosis during robotic surgery for colon cancer.</p><p><strong>Patients and methods: </strong>A total of 39 patients who underwent common enterotomy closure using bidirectional barbed sutures in intracorporeal overlap anastomosis during robotic surgery for colon cancer were enrolled in this study.</p><p><strong>Results: </strong>Although minor infectious complications were observed in a few cases, no anastomotic leakage or stricture was observed.</p><p><strong>Conclusion: </strong>Common enterotomy closure <i>via</i> a new method using bidirectional barbed sutures in intracorporeal overlap anastomosis may be a safe and useful procedure, especially in hospitals newly introducing intracorporeal anastomosis.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1567-1572"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of ¹⁰BPA.","authors":"Hironobu Yanagie, Syoji Maruyama, Kazuyuki Oyama, Yasuo Ono, Shinichi Kuroyama, Yasumasa Nonaka, Ryo Hatae, Yoshitaka Furuya, Minoru Suzuki, Shin-Ichiro Masunaga, Yoshinori Sakurai, Natsuko Kondo, Hiroki Tanaka, Akira Maruhashi, Koji Ono, Takumichi Sugihara, Hiroyuki Takahashi","doi":"10.21873/invivo.13948","DOIUrl":"https://doi.org/10.21873/invivo.13948","url":null,"abstract":"<p><strong>Background/aim: </strong>Boron neutron capture therapy (BNCT) is a novel treatment that induces targeted tumor cell damage through the selective accumulation of ¹⁰B compounds in cancer cells followed by the production of alpha and lithium particles using thermal neutron irradiation. Despite its potential, clinical applications of BNCT for recurrent gastrointestinal cancers remain limited. This study presents the first pilot clinical evaluation of BNCT using intravenous boronophenylalanine (¹⁰BPA) for such cancers.</p><p><strong>Case reports: </strong>Four patients with recurrent gastrointestinal cancers were enrolled in this phase I-II clinical study. All had tumors refractory to standard treatments, including surgery, chemotherapy, and radiotherapy. BNCT was performed using thermal neutron irradiation at Kyoto University Research Reactor. ¹⁰BPA was administered intravenously at 400 mg/kg, and no severe adverse effects were observed. Tumor responses varied, with one patient achieving partial response and three demonstrating stable disease at three months post-treatment. Notably, BNCT alleviated cancer-related symptoms, such as pain and nerve compression, improving patients' quality of life. Dosimetric evaluations confirmed effective tumor doses with acceptable exposure to surrounding normal tissues.</p><p><strong>Conclusion: </strong>BNCT is a promising modality for recurrent gastrointestinal cancers, offering symptom relief and potential antitumor effects. Its safety and feasibility were demonstrated in this study. Future research should explore fractionated BNCT and combination therapies with immunotherapy or targeted agents to enhance efficacy further.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1470-1491"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144008592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steroid Premedication Impact on Efficacy and Cutaneous Toxicity of Enfortumab Vedotin for Advanced Urothelial Carcinoma.","authors":"Nobuki Furubayashi, Manabu Mochida, Atsuhiro Kijima, Yushi Fujimoto, Motonobu Nakamura, Takahito Negishi","doi":"10.21873/invivo.13961","DOIUrl":"https://doi.org/10.21873/invivo.13961","url":null,"abstract":"<p><strong>Background/aim: </strong>The impact of steroid premedication on the efficacy and cutaneous toxicity of enfortumab vedotin (EV) in advanced urothelial carcinoma (UC) is unclear.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed consecutive patients with advanced UC who received EV after the failure of platinum-based chemotherapy and immune checkpoint inhibitors from December 2021 to November 2024.</p><p><strong>Results: </strong>Twenty-eight patients (male, n=16; median age, 71 years) were enrolled. Dexamethasone 6.6 mg was administered intravenously prior to EV in six (21.4%) patients. There were no differences in the overall response and disease control rates between patients with and without steroid premedication (<i>p</i>=0.653 and <i>p</i>>0.99, respectively). The progression-free survival was not significantly associated with or without steroid premedication (not estimable <i>vs.</i> 4.3 months, <i>p</i>=0.501). There were no marked differences in the incidence of all grades of EV-related cutaneous adverse events (AEs) between patients with and without steroid premedication (33.3% <i>vs.</i> 45.5%, <i>p</i>=0.673). There was no significant difference in the incidence of grade ≥3 EV-related cutaneous AEs between the patients with and without steroid premedication (16.7% <i>vs.</i> 36.4%, <i>p</i>=0.630). Multivariate analysis revealed that a performance status ≥2 was an independent prognostic factor for progression-free survival (hazard ratio=4.653, 95% confidence interval=1.263-17.140, <i>p</i>=0.021), and steroid premedication was not (<i>p</i> =0.869).</p><p><strong>Conclusion: </strong>In EV treatment, steroid premedication did not affect clinical outcomes. The incidence and severity of EV-related cutaneous toxicity tended to improve in patients who received steroid premedication, although no significant differences were observed.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1607-1614"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Chemopreventive and Antioxidant Effects of Spearmint Leaf Hydroethanolic Extract in HPV16-transgenic Mice.","authors":"Tiago M Jesus, Tiago Azevedo, Rita Silva-Reis, Tiago Ferreira, Elisabete Nascimento-Gonçalves, Catarina Medeiros, João Ferreira, Adelina Gama, Isabel Gaivão, Maria João Pires, Germano Lanzarin, Luís Félix, Carlos Venâncio, Rui Medeiros, Margarida M S M Bastos, Tiane C Finimundy, Lillian Barros, Rui M Gil DA Costa, Paula A Oliveira","doi":"10.21873/invivo.13934","DOIUrl":"https://doi.org/10.21873/invivo.13934","url":null,"abstract":"<p><strong>Background/aim: </strong>Human papillomavirus (HPV) is the most common sexually transmitted infectious agent and, in cases of persistent infection, may cause cancer. This study evaluated the toxicological and antitumor properties of <i>Mentha spicata</i> extract (MSE) in KP14HPV16 mice, which carry HPV16 oncogenes.</p><p><strong>Materials and methods: </strong>Thirty-three female FVB/n mice (<i>Mus musculus</i>), including 17 HPV-transgenic and 16 wild-type (WT) mice, were divided into six groups. The control groups received tap water (WT-C, <i>n</i>=5, and HPV-C, <i>n</i>=6), while the treatment groups received either 0.50 mg/ml MSE (WT-50 and HPV-50, <i>n</i>=6) or 0.55 mg/ml MSE (WT-55 and HPV-55, <i>n</i>=5) in drinking water for 28 days. Afterwards, animals were sacrificed, and blood and organs were collected for histopathological and biochemical analysis.</p><p><strong>Results: </strong>The main phenolic compounds in MSE were rosmarinic acid and luteolin-<i>O</i>-glucoronide. MSE did not significantly affect weight gain in WT mice; however, WT-55 gained significantly more weight than HPV-55. MSE demonstrated antioxidant activity as indicated by the modulation of hepatic superoxide dismutase and glutathione S-transferase (GST) activity, as well as renal GST activity, in MSE-treated HPV groups. MSE did not reduce histological lesion incidence or systemic inflammation in HPV16-transgenic mice.</p><p><strong>Conclusion: </strong>In general, while MSE was safe and exhibited antioxidant activity, it did not significantly impact HPV16-induced lesions, warranting further research to assess systemic effects with different concentrations and durations.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1303-1313"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Matrix Metalloproteinase-7 Genotypes With Nasopharyngeal Carcinoma Risk.","authors":"Liang-Chun Shih, Shih-Wei Hsu, Kai-Yuan Chen, Che-Lun Hsu, Yen-Fang Liu, Yun-Chi Wang, Hou-Yu Shih, Wen-Shin Chang, DA-Tian Bau, Chia-Wen Tsai","doi":"10.21873/invivo.13935","DOIUrl":"https://doi.org/10.21873/invivo.13935","url":null,"abstract":"<p><strong>Background/aim: </strong>Nasopharyngeal carcinoma (NPC) is a multifactorial malignancy influenced by Epstein-Barr virus (EBV) infection, genetic susceptibility, and environmental factors. Matrix metalloproteinase-7 (MMP-7), a key regulator of extracellular matrix remodeling, has been implicated in NPC progression. This study investigated the association between <i>MMP-7</i> rs11568818 and rs11568819 genotypes and NPC susceptibility in a Taiwanese cohort consisted of 208 NPC cases and 416 cancer-free controls.</p><p><strong>Materials and methods: </strong>The genotypic patterns of <i>MMP-7</i> rs11568818 and rs11568819 were revealed by utilizing PCR-RFLP methodology. In addition, the interaction between <i>MMP-7</i> genotypes and lifestyle factors (including smoking, alcohol consumption, and betel quid chewing) was also analyzed in a stratified manner.</p><p><strong>Results: </strong>Genotypic distribution analysis of <i>MMP-7</i> rs11568818 showed no significant association with NPC risk (<i>p</i> for trend=0.4641). Individuals carrying the AG (OR=1.22, 95%CI=0.79-1.90, <i>p</i>=0.4384) or GG (OR=1.74, 95%CI=0.52-5.79, <i>p</i>=0.5539) genotypes exhibited a modestly elevated, but statistically non-significant, risk compared to AA carriers. Similarly, allelic frequency analysis indicated that the G allele did not significantly contribute to NPC susceptibility (OR=1.28, 95%CI=0.87-1.87, <i>p</i>=0.2433). Stratified analysis revealed a significant interaction between <i>MMP-7</i> rs11568818 and smoking status (<i>p</i> for trend=0.0018). Among smokers, AG and GG genotypes were associated with an increased NPC risk (AG: OR=2.70, 95%CI=1.34-5.44, <i>p</i>=0.0076; GG: OR=9.27, 95%CI=1.01-84.66, <i>p</i>=0.0345), which remained significant after adjusting for confounders (adjusted OR=2.53, 95%CI=1.27-4.88; adjusted OR=7.89, 95%CI=1.02-47.38). No interactions were observed with alcohol consumption or betel quid chewing. Additionally, no polymorphic genotypes were detected for <i>MMP-7</i> rs11568819 in the studied population.</p><p><strong>Conclusion: </strong>While <i>MMP-7</i> rs11568818 does not directly influence NPC susceptibility in a Taiwanese population, its interaction with smoking may contribute to elevated NPC risk.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1314-1324"},"PeriodicalIF":1.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}